ClinicalTrials.gg
Enrolling by invitationNCT07089017Updated Nov 12, 2026

Anesthetic Management Guided by the Medstrom Instrument

An interventional study of medstrom仪器 in Pain Management, sponsored by Chinese PLA General Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Chinese PLA General Hospital · Not applicable, Interventional, and Other

How we know

Updated Nov 12, 2026Now Enrolling by invitationFirst site in China+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This clinical trial seeks to evaluate the feasibility of the Medstrom device for integrated real-time monitoring of pain, sedation, and neuromuscular blockade during laparoscopic radical colectomy. By addressing limitations of conventional multi-device monitoring systems-including data conflicts, interpretation delays, and elevated costs-the study examines whether Medstrom can comprehensively assess intraoperative patient status and effectively guide anesthesia management using validated reference metrics.

Key questions being investigated include:

  1. Whether Medstrom can concurrently generate reliable pain, sedation, and neuromuscular indices through a single platform, and if these outputs demonstrate significant correlation with gold-standard measures (HRV for pain, BIS for sedation, TOF for neuromuscular blockade);
  2. Whether integrated monitoring reduces intraoperative decision latency (e.g., accelerated pain detection) and mitigates inter-device interference (e.g., BIS distortion by neuromuscular agents);
  3. Whether Medstrom introduces device-related adverse events (e.g., cutaneous irritation, signal misinterpretation) while potentially reducing anesthesia complications (e.g., respiratory depression, intraoperative awareness).

Researchers will randomize patients undergoing elective laparoscopic radical colectomy into two groups:

  1. Group T(Medstrom -guided):an intervention group receiving continuous multimodal monitoring via Medstrom,
  2. Group C (Conventional):a control group undergoing conventional monitoring (BIS + TOF + hemodynamic parameters).

Synchronized data will be captured at eight predefined intraoperative timepoints for correlation analysis between Medstrom-derived indices and conventional metrics.

Read the detailed description

This prospective randomized controlled trial (RCT) aims to evaluate the feasibility and safety of the integrated Medstrom monitoring system for real-time, comprehensive assessment of pain, sedation level, and neuromuscular blockade (NMB) during laparoscopic radical colectomy. It addresses significant limitations of conventional fragmented monitoring systems, such as data conflicts between independent devices (e.g., BIS for sedation, TOF for NMB, HRV for pain), delayed clinical interpretation, and suboptimal resource utilization.

The Medstrom technology utilizes palmar/plantar PAM sensors to objectively quantify pain via skin conductance peaks (SCP). SCPs are generated by emotional sweating triggered via spinal nociceptive reflexes, offering key advantages: objective pain quantification (SCP amplitude correlates with stimulus intensity), rapid response (within 1-2 seconds to noxious stimuli), resilience against hemodynamic instability, temperature variations, or medications, and the unique capability to simultaneously output validated sedation and neuromuscular indices. This single-device integration aims to replace the need for separate BIS, TOF, and HRV monitors.

The study design involves 45 patients (adjusted for 10% dropout from n=40) aged 18-65 years with ASA physical status I-III and confirmed colon cancer, undergoing elective laparoscopic radical colectomy. Key exclusions include BMI ≥30, significant organ dysfunction, neurological/neuromuscular disorders, and pregnancy. Participants are randomized into two groups:

  1. Medstrom-Guided Group (Intervention): Continuous monitoring using palmar/plantar sensors with real-time display of integrated pain, sedation, and NMB indices guiding anesthesia management.
  2. Conventional Monitoring Group (Control): Standard care using separate BIS (target 40-60) + TOF + standard hemodynamic monitoring.

A standardized anesthesia protocol is employed for both groups: Induction with Propofol (1.5-2.5 mg/kg) + Sufentanil (0.2-0.4 μg/kg) + Rocuronium (0.6-1.0 mg/kg), and Maintenance with Propofol (4-12 mg/kg/h) + Remifentanil (0.1-0.2 μg/kg/min) + bolus Rocuronium/Sufentanil as needed. Data collection occurs at 8 critical intraoperative timepoints, including intubation, skin incision, pneumoperitoneum, surgical end, and pre/post supplemental sufentanil administration.

The primary endpoints focus on establishing the feasibility and correlation of the Medstrom indices against current gold standards:

  • Correlation of Medstrom-Pain vs. HRV (Pearson/Spearman).

Feasibility is defined by statistically significant correlations (p\<0.05, adjusted for multiple comparisons using Bonferroni/Dunn-Šidák).

Secondary outcomes include hemodynamic stability (HR/MAP fluctuations), total anesthetic consumption, device-related adverse events (e.g., skin irritation, signal errors), and analysis of interactions between the integrated indices (using SEM/pathway analysis).

The statistical approach is based on a sample size of 40 (calculated for multivariate repeated measures: α=0.05, β=0.1/power=90%, effect size f²=0.15, variable correlation ρ=0.4), increased to N=45 to account for a 10% dropout rate. Analyses include correlation (95% CIs), consistency (Bland-Altman/ICC for agreement), multivariable comparisons (Hotelling's T² for correlated outcomes), and time effects (Linear mixed models with random intercepts).

This study holds innovative significance as the first RCT to validate a single-device, triple-parameter integrated monitoring system (pain, sedation, NMB) specifically in major abdominal surgery. It addresses critical clinical gaps: providing objective pain quantification (replacing subjective hemodynamic interpretation), minimizing device interference issues (e.g., BIS distortion by neuromuscular agents), and enhancing resource efficiency. The potential clinical impact includes reducing the risk of intraoperative awareness/pain recall and establishing a framework for more cost-effective and streamlined anesthesia management.

02

Conditions studied

  • Pain Management
03

In context

Lead sponsor

Chinese PLA General Hospital is the lead sponsor of 574 studies on the registry; 209 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Timeframe \& Location: Patients treated at the First Medical Center of the Chinese PLA General Hospital between June 2025 and December 2026.

    2. Age: 18 to 65 years old. 3. Diagnosis: confirmed colon cancer requiring laparoscopic radical resection.

    4. Physical Status: (ASA) Physical Status Class I-III.

    5. : Patients who voluntarily participate in the study and provide written informed consent.

Exclusion criteria

Exclusion Criteria:

- 1. (BMI): BMI ≥ 30 kg/m². 2. Organ Dysfunction: Severe concomitant cardiac, pulmonary, hepatic, or renal dysfunction.

3. Neurological Conditions:

  • History of autonomic nervous system disorders.
  • Current use of medications affecting autonomic nervous system function.
  • History of neuromuscular dysfunction. 4. Pregnancy/Lactation: Pregnant or lactating women. 5. Recent Surgery: History of secondary surgery within the preceding month. 6. Psychiatric/Cognitive Conditions:
  • History of psychiatric disorders or cognitive impairment.
  • History of psychotropic or narcotic drug abuse.
  • Significant communication barriers.

Withdrawal Criteria:

1.Requirement for conversion to open surgery or other significant deviation from the planned laparoscopic approach due to intraoperative findings.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • No intervention
    No Intervention: Group C

    Standard care using separate BIS (target 40-60) + TOF + standard hemodynamic monitoring.

  • Experimental
    Experimental:Group T

    Continuous monitoring using palmar/plantar sensors with real-time display of integrated pain, sedation, and NMB indices guiding anesthesia management.

    Device: medstrom仪器

Interventions

  • Devicemedstrom仪器

    In addition to conventional monitoring methods, such as electrocardiography (ECG), bispectral index (BIS), and train-of-four (TOF) monitoring, Medstrom instruments were utilized to assess and monitor the patient's pain, sedation, and muscle relaxation status.

06

What researchers measure

Primary outcomes

  1. Correlation between HRV and the Medstrom Instrument Pain Index

    The correlation between HRV and the pain index of the Medstrom instrument under sedation and muscle relaxation with Bis maintained at 40-60 and TOF maintained below 90%

    Time frame: From the beginning to the end of the operation

Secondary outcomes

  1. Heart rate

    Heart rate (bpm) at each time point.

    Time frame: From the beginning to the end of the operation

  2. The total amount of anesthetic drugs

    Total amount of relevant narcotic drugs

    Time frame: From the beginning to the end of the operation

  3. Interaction of related indicators

    Whether there is an interaction between the relevant indices

    Time frame: From the beginning to the end of the operation

  4. Mean arterial pressure

    Mean arterial pressure (mmHg) at each time point.

    Time frame: From the beginning to the end of the operation

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Sep 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2025
First posted
Jul 28, 2025
StartActual
Feb 1, 2026
Primary completionActual
Sep 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 12, 2026
Sites
1 site added — first site in China
Show site
  • Chinese PLA General Hospital · Beijing, China
Nov 12, 2026
Contact
No study contact listed any more: removed q•••@sina.com · •••7586
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Enrolling by invitation
    1 site added — first site in China
    Show site
    • Chinese PLA General Hospital · Beijing, China
    Contact No study contact listed any more: removed q•••@sina.com · •••7586
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07089017
Responsible party
Peiqi Wang (professor, Chinese PLA General Hospital) — Principal investigator
First posted
Jul 28, 2025
Start date
Feb 1, 2026
Primary completion
Sep 1, 2026
Completion
Dec 31, 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Pei qi Wang
principal investigator · The Firsst Medical Center ,Chinese PLA General Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion